Research output: Contribution to journal › Article › peer-review
Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer. / Shevchenko, Julia A.; Khristin, Alexander A.; Kurilin, Vasily V. et al.
In: Oncology Reports, Vol. 43, No. 2, 02.2020, p. 671-680.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer
AU - Shevchenko, Julia A.
AU - Khristin, Alexander A.
AU - Kurilin, Vasily V.
AU - Kuznetsova, Maria S.
AU - Blinova, Darya D.
AU - Starostina, Natalya M.
AU - Sidorov, Sergey V.
AU - Sennikov, Sergey V.
N1 - Publisher Copyright: © 2020 Spandidos Publications. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2
Y1 - 2020/2
N2 - Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL-12 and IL-18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease-free period was performed for 3 years after surgery. The use of antigen-loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.
AB - Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL-12 and IL-18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease-free period was performed for 3 years after surgery. The use of antigen-loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.
KW - Breast cancer
KW - Cancer immunotherapy
KW - Cytotoxic T lymphocytes
KW - Cytotoxicity
KW - Dendritic cells
KW - T-helper cell polarization
UR - http://www.scopus.com/inward/record.url?scp=85077732371&partnerID=8YFLogxK
U2 - 10.3892/or.2019.7435
DO - 10.3892/or.2019.7435
M3 - Article
C2 - 31894312
AN - SCOPUS:85077732371
VL - 43
SP - 671
EP - 680
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 2
ER -
ID: 23101918